Looking for info on Manny Backus “Boston Biotech” Stock

By jstep8856, March 11, 2014

This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.

Hello Travis
Just saw a teaser about a ”Boston Biotech” stock that is poised to show 400 to 700% profits this year from Penny Stock gurus Manny Backus. Can you ”thinkolate” this one. Sounds pretty promising!
Thanks for your thoughts. They’re always appreciated!

Share Your Thoughts

ShowHide Comments (4)
    1. 4001 |
      frank archambeau
      frank archambeau
      Mar 12 2014, 03:53:44 am

      Paul ,try BSX Boston scientific. I have seen that teased before but I don’t know of ant new developments..

    2. Andy Bell
      Mar 13 2014, 08:55:18 pm

      Greenfire67 is 100% correct on Ziopharm. Manny Backus wrote up a major article
      December 15, 2013 on it which you can read. He was promoting this stock on his Conscensus Picks which I still subscribe to. At that time he was advising subscribers
      to buy below $4 and to sell at $9. The drug in question is AD-RTS-IL-12 which is in
      phase two trials as of December 15, 2013. Also, the two partners that Ziopharm
      is working with are Intrexon (XON) and Mesoblast. The insider guy in the tease that
      bought 2,8577,000 shares for a cool ten million is Randall Kirk. They also issued 14.3 million shares last March which caused shares to plummet to $3.50 a stub. The title
      of the article is “Ziopharm: Finally a Cure in the War on Cancer?” which you can access
      by typing in ZIOP on the Finviz site, and scrolling down for this article below the stock
      chart. I’m not sure but Dr. Karma might have something to say about it in the Benitech

    What These Icons Mean

    • The user who posted this comment is a Stock Gumshoe Premium Member (also known as an "IRREGULAR").
    • This user regularly writes articles for Stock Gumshoe. They may or may not be the author of the current article.
    • This user's comments have been "liked” by at least a few members of the Stock Gumshoe community.
    • This user has commented widely, with input that has been liked enough to earn a two-thumbs-up rating from other readers.
    • This is the highest rating a user can get. They are among the most respected commentors of our community.